Creating new vaccines to fight antibiotic-resistant bacteria
Official title: Methods to synthesize oligosaccharide-fusion protein conjugates and enhancement of their antigenicity
Funded at University of Toledo · NIH-10745655 · Data updated 2026-11-12
This study is working on new vaccines to help fight tough infections caused by antibiotic-resistant bacteria, like Pseudomonas aeruginosa, so that patients can have better treatment options for these challenging infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Toledo NIH-funded |
| Lab location | 1 site (Toledo, United States) |
| Project start | January 1, 2020 |
| Project end | December 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $465,901 |
| NIH project number | 5R01AI148570-05 |
| Project ID | NIH-10745655 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of infections caused by antibiotic-resistant bacteria, particularly those with compromised immune systems.
✕Less likely to help
Patients who are not at risk for infections from antibiotic-resistant bacteria may not receive any benefit from this research.
What this research studies
This research focuses on developing innovative vaccines to combat antibiotic-resistant bacteria, specifically targeting the ESKAPE pathogen Pseudomonas aeruginosa. The approach involves chemically synthesizing unique oligosaccharide epitopes from the bacteria's lipopolysaccharides and conjugating them with protective protein domains. By using advanced synthetic biology techniques, the researchers aim to enhance the immune response against these pathogens, potentially leading to more effective vaccines. Patients may benefit from improved treatments for infections caused by these resistant bacteria.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective vaccines against antibiotic-resistant infections, improving patient outcomes.
How similar studies have gone: Other research has shown promise in developing glycoconjugate vaccines, but this specific approach targeting ESKAPE pathogens is relatively novel.
Where this research is happening
-
University of Toledo
Toledo, United States Active
Researchers
- Principal investigator: Sucheck, Steven — University of Toledo
- Study coordinator: Sucheck, Steven
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.